NCT01024140

Open Trial of Escitalopram Treatment for Male Subjects With Posttraumatic Stress Disorder

• Status: Completed
• Phase: N/A
• Study type: Interventional
• Enrollment: 16 (actual)
• Sponsor: Northern California Institute of Research and Education · Academic / Other
• Sex: Male
• Age: 20 Years – 60 Years
• Healthy volunteers: Not accepted

Summary

The primary aim of this pilot study is to test the efficacy of the selective serotonin re-uptake inhibitor, Escitalopram, in the treatment of posttraumatic stress disorder (PTSD) in an open clinical trial. A secondary aim is to determine whether treatment with escitalopram increases plasma allopregnanolone levels in patients with PTSD and if increases in allopregnanolone levels are correlated with treatment efficacy.

Conditions

• Chronic Posttraumatic Stress Disorder

Interventions

Type	Name	Description
DRUG	Escitalopram	Subjects were started on 5mg escitalopram. Medication was increased as tolerated in weekly 2.5, 5 or 10 mg increments, until a maximally tolerated dosage or a clinical response was achieved. The final dosage ranged from 5 to 20 mg/day.

Timeline

• Start date: 2003-02-01
• Primary completion: 2004-12-01
• Completion: 2004-12-01
• First posted: 2009-12-02
• Last updated: 2009-12-02